Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

UPDATE: Valeant Releases Details On Hospital Discount Plan For Heart Drugs

XTALKS VITALS NEWS

Hospital Pharmacy

According to a statement released by Valeant, all hospitals will be eligible to receive a 10 percent rebate on the heart drugs, with some high volume centers benefitted from as much as a 40 percent discount.

Share this!

May 18, 2016 | by Sarah Massey, M.Sc.

Amid criticism over Valeant’s failure to deliver on promised hospital discounts for two of their heart drugs, the company has released the details of its rebate program for Isuprel and Nitropress. While these volume-based discounts were announced earlier this year, the company has faced considerable criticism from Congress over drug pricing and patient access.

According to a statement released by Valeant, all hospitals will be eligible to receive a 10 percent rebate on the heart drugs, with some high volume centers benefitted from as much as a 40 percent discount. Valeant’s new Patient Access and Pricing committee has also vowed to neither increase the price of the drugs, nor decrease the discounts available.



While this is welcome news to hospital pharmacy administrators, Valeant has already raised the price of Isuprel and Nitropress by 720 percent and 310 percent, respectively, since acquiring the drugs in early 2015. Representatives from Valeant appeared in front of the Senate Aging Committee on April 27, where they were confronted by senators regarding the lack of hospitals that had received the discounts.

With the release of the statement earlier this week, it looks like Valeant is making strides to ensure hospitals get the drugs at reduced prices. According to the company, the discounts will likely be offered to group purchasing organizations as opposed to directly dealing with individual hospitals.

“Under this new program, the discounts we previously implemented for Nitropress and Isuprel will be simplified and more accessible,” said Joseph Papa, CEO of Valeant. “I understand the concerns our partners in the health care community have had about the pricing of these drugs, and we want to ensure hospitals and patients can get the drugs they need.

“I also want to thank the Senate Committee on Aging and the House Committee on Oversight and Government Reform for the attention they have brought to this issue, and specifically to gaps they identified in the previous program,” said Papa. “We are committed to getting this right.”


Keywords: Drug Pricing, Heart Drug, Hospital Pharmacy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.